Review
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2016; 8(3): 248-257
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248
Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival
Marianne Sinn, Marcus Bahra, Timm Denecke, Sue Travis, Uwe Pelzer, Hanno Riess
Marianne Sinn, Sue Travis, Uwe Pelzer, Hanno Riess, Department of Medical Oncology and Haematology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany
Marcus Bahra, Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany
Timm Denecke, Institute of Radiology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany
Author contributions: Sinn M, Bahra M and Denecke T wrote the manuscript; Travis S, Pelzer U and Riess H revised and corrected the manuscript.
Conflict-of-interest statement: Marianne Sinn received travel support and honoraria for scientific presentations by Bayer Healthcare, Celgene, Roche, Leo Pharma. Marcus Bahra received travel support by Celgene. Timm Denecke received travel support and honoraria for scientific presentations by Bayer Healthcare, Siemens Medical Solutions, Toshiba, Novartis. Sue Travis has no conflict of interests to declare. Uwe Pelzer received travel support and honoraria for scientific presentations from Celgene, Amgen, BBraun. Hanno Riess received fees for serving as a speaker for Aspen Europa, Bayer Health Care AG, Bristol Myers Squipp, Boehringer Ingelheim, Daiichi-Sankyo, Leo Pharma, Novartis Pharma, Pfizer Pharma and Sanofi-Aventis.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. med. Marianne Sinn, MD, Department of Medical Oncology and Haematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. marianne.sinn@charite.de
Telephone: +49-30-450553222 Fax: +49-30-450553959
Received: June 29, 2015
Peer-review started: July 2, 2015
First decision: August 25, 2015
Revised: December 1, 2015
Accepted: December 18, 2015
Article in press: December 21, 2015
Published online: March 15, 2016
Core Tip

Core tip: Pancreatic cancer remains one of the most challenging tumor entities and is predicted to become the second leading cause of cancer deaths. More effective chemotherapeutic concepts in combination with early and exact imaging and more extensive surgical approaches may improve the rate of cure.